APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial

Ville Pettilä, Lea Kyhälä, Marja-Leena Kylänpää, Ari Leppäniemi, Minna Tallgren, Antti Markkola, Pauli Puolakkainen, Heikki Repo, Esko Kemppainen, Ville Pettilä, Lea Kyhälä, Marja-Leena Kylänpää, Ari Leppäniemi, Minna Tallgren, Antti Markkola, Pauli Puolakkainen, Heikki Repo, Esko Kemppainen

Abstract

Introduction: Previous human studies have shown low activity of protein C (APC) in severe acute pancreatitis (SAP). This, together with the findings in animal models, suggests that activated protein C (APC) may protect against pancreatic injury and ameliorate the disease. We, therefore, evaluated its effect on multiple organ dysfunction (MOD) measured by the SOFA (Sequential Organ Failure Assessment) and on organ-failure-free days, and the safety of APC in SAP.

Methods: A prospective double blind randomized pilot study was use. The study occurred in one university hospital tertiary intensive care unit (ICU) with eight beds. The patients were chosen according to the following inclusion criteria: 1) Those admitted to the hospital < 96 h from the onset of pain, 2) Those who had a three-fold increase in serum amylase over normal upper range or/and in whom computed tomography (CT) verification of SAP was noted, 3) Those who had one or more organ dysfunction (OD), and 4) Those in whom less than 48 hours had passed since their first OD. Of a total of 215 adult patients with SAP screened between June 2003 and August 2007, 158 fulfilled the study inclusion criteria. After exclusions 32 patients were randomized to the study. The intervention consisted of APC (N = 16) administered intravenously for 96 hours with a dose of 24 μg/kg/hour or placebo (N = 16) with a similar infusion rate. The sample size for the study was calculated according to the primary end-point: the change in SOFA during study drug infusion (Days 0 and 5). Comparisons between the study groups were performed using patient-related changes and calculation of difference in means (DIM, 95% CIs) and regarding categorical variables with Fisher's exact test. For all comparisons P < 0.05 was considered significant.

Results: No serious bleeding was detected clinically or by CT scans in either group. No significant difference in SOFA score change between the APC and placebo groups was found (difference in means (DIM) +2.3, 95% CI -0.7 to +5.3). Treatment with APC was associated with an increase in serum levels of both total and conjugated bilirubin. No differences in ventilator-free days, in renal replacement therapy-free days, in vasopressor-free days, or in days alive outside the hospital were detected.

Conclusions: No serious bleeding or differences in the evolution of MOD were detected between APC and the placebo. Instead we found an increase in serum bilirubin in the APC group compared to the placebo group in patients with SAP.

Trial registration: ClinicalTrials.gov NCT01017107.

Figures

Figure 1
Figure 1
Flow-chart of the study.

References

    1. Frossard JL, Hadengue A, Pastor CM. New serum markers for the detection of severe acute pancreatitis in humans. Am J Resp Crit Care Med. 2001;164:162–170.
    1. Halonen KI, Pettilä V, Leppäniemi AK, Kemppainen EA, Puolakkainen PA, Haapiainen RK. Multiple organ dysfunction associated with severe acute pancreatitis. Crit Care Med. 2002;30:1274–1279. doi: 10.1097/00003246-200206000-00019.
    1. de Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. Gut. 1995;37:121–126. doi: 10.1136/gut.37.1.121.
    1. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–1800.
    1. Ottesen LH, Bladbjerg EM, Osman M, Lausten SB, Jacobsen NO, Gram J, Jensen SL. Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg. 1999;16:486–495. doi: 10.1159/000018774.
    1. Lindstrom O, Kylänpaa L, Mentula P, Puolakkainen P, Kemppainen E, Haapiainen R, Fernandez JA, Griffin JH, Repo H, Petäjä J. Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care. 2006;10:R16. doi: 10.1186/cc3966.
    1. Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, Fernandez-del Castillo C. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg. 2006;141:670–676. doi: 10.1001/archsurg.141.7.670.
    1. Chen P, Zhang Y, Qiao M, Yuan Y. Activated protein C, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases. J Gastroenterol. 2007;42:887–896. doi: 10.1007/s00535-007-2104-2.
    1. Yamanel L, Mas MR, Comert B, Isik AT, Aydin S, Mas N, Deveci S, Ozyurt M, Tasci I, Unal T. The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit Care. 2005;9:R184–R190. doi: 10.1186/cc3485.
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001.
    1. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med. 2007;33:396–399. doi: 10.1007/s00134-007-0556-8.
    1. Mackenzie AF. Activated protein C: do more survive? Intensive Care Med. 2005;31:1624–1626. doi: 10.1007/s00134-005-2829-4.
    1. Woodward B, Cartwright M. Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies. J Crit Care. 2009;24:595–602. doi: 10.1016/j.jcrc.2008.11.011.
    1. Barie PS. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) 2007;8:491–494. doi: 10.1089/sur.2007.9980.
    1. Kirschenbaum L, Astiz M. Acute pancreatitis: a possible role for activated protein C? Crit Care. 2005;9:243–244. doi: 10.1186/cc3515.
    1. Jamdar S, Siriwardena AK. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis. Crit Care. 2005;9:321–322. doi: 10.1186/cc3777.
    1. Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586–590.
    1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332–1341. doi: 10.1056/NEJMoa050935.
    1. Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand J-A, Skerrett SJ, Stapleton RD, Ware LB, Waldman CS. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med. 2004;32:2524–2536. doi: 10.1097/01.CCM.0000148222.09869.92.
    1. Pettilä V, Pettilä M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in prediction of hospital mortality in the critically ill patients. Crit Care Med. 2002;28:1705–1711. doi: 10.1097/00003246-200208000-00005.
    1. Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008;12:R161. doi: 10.1186/cc7160.
    1. Schoenfeld DA, Bernard GR. ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30:1772–1777. doi: 10.1097/00003246-200208000-00016.
    1. Mortele KJ, Wiesner W, Intriere L, Shankar S, Zou KH, Kalantari BN, Perez A, vanSonnenberg E, Ros PR, Banks PA, Silverman SG. A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome. AJR Am J Roentgenol. 2004;183:1261–1265.
    1. Guyatt GH, Sackett DL, Cook DJ. Evidence-Based Medicine Working Group. User' s guides to the medical literature II. How to use an article about therapy or prevention B. What were the results and will they help me in caring for my patients? JAMA. 1994;271:59–63. doi: 10.1001/jama.271.1.59.
    1. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330.
    1. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, Bernard GR. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31:834–840. doi: 10.1097/01.CCM.0000051515.56179.E1.
    1. Machala W, Wachowicz N, Komorowska A, Gaszynski W. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Med Sci Monit. 2004;10:CS31–CS36.
    1. Ping C, Youngping Z, Minmin Q, Weiyan Y, Yaozong Y. Activated protein C improves severity of severe acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin. Dig Dis Sci. 2009. in press .
    1. Akay S, Ozutemiz O, Yenisey C, Genc N Simsek, Yuce G, Batur Y. Use of activated protein C has no avail in the early phase of acute pancreatitis. HPB (Oxford) 2008;10:459–463.
    1. Nacira S, Ferhat M, Olivier D, Valerie C, Solene C, Chantal M, Sebastien G, Pierre A, Andriantsitohaina R, Veronique R, Michel S, Thomas L, Patrick L, Bruno L. Activated protein C improves LPS-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med. 2008. in press .
    1. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med. 2005;33:368–372. doi: 10.1097/01.CCM.0000153415.04995.88.
    1. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med. 2001;29:S48–S51. doi: 10.1097/00003246-200107001-00018. discussion 51-52.
    1. Neyrinck AP, Liu KD, Howard JP, Matthay MA. Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol. 2009;158:1034–1037. doi: 10.1111/j.1476-5381.2009.00251.x.
    1. Radenkovic D, Bajec D, Karamarkovic A, Stefanovic B, Milic N, Ignjatovic S, Gregoric P, Milicevic M. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas. 2004;29:152–156. doi: 10.1097/00006676-200408000-00010.
    1. Turpin DL. CONSORT and QUOROM guidelines for reporting randomized clinical trials and systematic reviews. Am J Orthod Dentofacial Orthop. 2005;128:681–685. doi: 10.1016/j.ajodo.2005.10.010.
    1. Takala J. Better conduct of clinical trials: the control group in critical care trials. Crit Care Med. 2009;37:S80–S90. doi: 10.1097/CCM.0b013e3181922bf4.
    1. Juneja D, Gopal PB, Ravula M. Scoring systems in acute pancreatitis: Which one to use in intensive care units? J Crit Care. 2010;25:358–e9-358-e15. doi: 10.1016/j.jcrc.2009.12.010.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅